EU committee backs Mounjaro for chronic weight management

A European Medicines Agency committee recommended on Nov. 9, 2023, that Mounjaro (tirzepatide) be authorized in the European Union for chronic weight management, including weight loss and weight maintenance ^[1]. The recommendation covered use as an adjunct to a reduced-calorie diet and increased physical activity ^[1].

The European Commission issued its final decision about a month later, on Dec. 11, 2023, completing the change to the medicine's marketing authorization ^[1].

Who the recommendation covers

The proposed EU indication was for adults with an initial body mass index of 30 kg/m² or more, the range defined as obesity, or a BMI of 27 kg/m² to under 30 kg/m², defined as overweight, when at least one weight-related comorbid condition is also present ^[1].

The application, filed as variation II/0007, was an extension of indication rather than a new product approval ^[1]. Tirzepatide was already authorized in the EU under the Mounjaro brand name before this procedure.

What the evidence was

The recommendation was based on a global, pivotal phase 3 study coded I8F-MC-GPHK, known as SURMOUNT-1, plus five supportive phase 3 studies, SURPASS-1 through SURPASS-5 ^[1].

SURMOUNT-1 was a randomized, double-blind, placebo-controlled trial that tested tirzepatide given once weekly in participants without type 2 diabetes who had obesity, or who were overweight with weight-related conditions ^[1]. The five supportive studies were conducted in participants with type 2 diabetes and a BMI of 27 kg/m² or higher ^[1].

The procedural document does not include SURMOUNT-1's weight-loss results, so the size of the average weight change behind the recommendation has not been reported here.

The approval updated sections 4.1, 4.8, 5.1 and 5.2 of the Summary of Product Characteristics, the technical label used by prescribers in the EU, and the package leaflet was updated to match ^[1]. A version 2.1 of the risk management plan, the document companies use to track safety issues after approval, was also submitted ^[1].

Why it matters for patients

The decision changed what Mounjaro is officially cleared to treat in the European Union, from type 2 diabetes alone to type 2 diabetes and chronic weight management ^[1]. For patients in the EU, that means the weight-management use sits inside the approved label rather than outside it, with the dosing, safety and trial information that regulators reviewed written into the product information ^[1].

This was a European Union action. It does not by itself change what regulators elsewhere, including the US Food and Drug Administration, have authorized.

Label language matters because it shapes what a prescriber can offer and what a pharmacy can dispense for a given purpose, and because the leaflet patients receive describes the studied uses and known side effects ^[1]. The EU label for this indication specifies adults with obesity, or with overweight plus at least one weight-related condition, and describes the drug as an addition to diet and exercise rather than a replacement for them ^[1].

What happens next

The Dec. 11, 2023, Commission decision finalized this specific variation ^[1]. Under the EU rules described in the document, a Commission decision is issued within two months of the committee opinion for certain variations, or within one year for other procedures ^[1].

The same procedural record shows the Mounjaro label has continued to change since then. An extension covering moderate-to-severe obstructive sleep apnea and obesity drew a committee opinion on Dec. 12, 2024, with a Commission decision on Feb. 14, 2025 ^[1]. A further update based on the SUMMIT trial in people with a type of heart failure and obesity received a committee opinion on Jan. 29, 2026 ^[1].

An earlier extension, decided April 19, 2024, added six Mounjaro pen strengths for the EU market, from 2.5 mg to 15 mg per dose ^[1].